XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.
Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.
PetDx® – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company's flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.
Cortica Inc. is a healthcare company that specializes in providing neurological therapies for children with autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers a range of services including diagnoses for autism, ADHD, developmental delays, and other developmental differences. The company's treatment approach is tailored to each child, based on a comprehensive understanding of their neurobiology and developmental profile. Cortica provides customized treatment programs through in-home, in-clinic, and telehealth services. Its offerings encompass various interventions such as gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and multiple therapeutic modalities including ABA therapy, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company operates centers in several locations across California, including Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
Cortica Inc. is a healthcare company that specializes in providing neurological therapies for children with autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers a range of services including diagnoses for autism, ADHD, developmental delays, and other developmental differences. The company's treatment approach is tailored to each child, based on a comprehensive understanding of their neurobiology and developmental profile. Cortica provides customized treatment programs through in-home, in-clinic, and telehealth services. Its offerings encompass various interventions such as gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and multiple therapeutic modalities including ABA therapy, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company operates centers in several locations across California, including Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, that specializes in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions. Its primary focus is on TP-03, a novel treatment currently in Phase IIb/III trials for blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. The company is also advancing additional candidates, including TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and community malaria reduction. Tarsus aims to address significant unmet medical needs in various therapeutic areas, initially concentrating on eye care where treatment options are limited. Founded in 2016, Tarsus Pharmaceuticals continues to expand its pipeline to include diverse diseases across different medical fields.
ShiraTronics develops neuromodulation technology to combat debilitating chronic migraine. The company is driven by a mission to transform the lives of those living with chronic migraine.
Verix Health is developing a suite of actively steerable surgical devices enabling minimally invasive diagnosis and treatment of lesions in difficult-to-access anatomies. The company was founded by Professor Mark Yim, PhD and PCI Ventures at the University of Pennsylvania and incubated at the Pennovation Center in Philadelphia.
Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape. Bardy Diagnostics uses his expertise to develop cardiac monitoring solutions that help physicians obtain more accurate information about actionable events in the hopes of saving lives. The company's mission is to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses. Bardy Diagnostics was founded in 2013 and is headquartered in Seattle, Washington, USA.
Cortica Inc. is a healthcare company that specializes in providing neurological therapies for children with autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers a range of services including diagnoses for autism, ADHD, developmental delays, and other developmental differences. The company's treatment approach is tailored to each child, based on a comprehensive understanding of their neurobiology and developmental profile. Cortica provides customized treatment programs through in-home, in-clinic, and telehealth services. Its offerings encompass various interventions such as gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and multiple therapeutic modalities including ABA therapy, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company operates centers in several locations across California, including Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies aimed at addressing unmet medical needs for patients globally. The company's flagship technology, known as Electrical Nerve Block, targets chronic pain conditions, including neuroma and residual limb pain, chronic post-surgical pain, and chronic migraine. Neuros Medical also offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and associated external devices. Established in 2008, the company is dedicated to advancing innovative solutions for pain management.
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before. The company's platform includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure. It was founded in 2007 and is based in Lisle, Illinois.
Spirox is a California-based medical device company improving the quality of life for patients suffering from nasal obstruction. They are formerly known as Nasoform. Their first product, the LATERA absorbable nasal implant is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization. Spirox was founded in 2011 and is headquartered in Menlo Park, California.
Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.
Spirox is a California-based medical device company improving the quality of life for patients suffering from nasal obstruction. They are formerly known as Nasoform. Their first product, the LATERA absorbable nasal implant is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). The company intends to use the funds to complete development, seek US marketing authorization, and initiate product commercialization. Spirox was founded in 2011 and is headquartered in Menlo Park, California.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at addressing pain management while mitigating the risks of prescription drug abuse. The company utilizes its proprietary DETERx platform technology, which ensures that its formulations maintain extended-release and safety profiles even when subjected to common methods of misuse such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an abuse-deterrent, extended-release oral formulation of oxycodone, and Nucynta products, which consist of both extended-release and immediate-release formulations of tapentadol. These offerings are designed to manage chronic pain and provide effective treatment solutions while incorporating tamper-resistant features to combat non-medical use. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical was incorporated in 2002 and has focused on building a portfolio of innovative products that align with evolving patient needs and regulatory standards.
Lyric is a clinical-stage company developing novel gastrointestinal therapeutics for unmet medical needs in the hospital setting. It was founded in 2013 and is headquartered in San Francisco, California.
Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for obstructive sleep apnea (OSA). The company has created the Inspire system, a neurostimulation technology designed to provide safe and effective treatment for moderate to severe OSA. This system employs a proprietary Upper Airway Stimulation (UAS) therapy that utilizes established technologies from cardiac pacing and neurostimulation. Additionally, Inspire is developing a novel closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to keep the airway open. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire primarily generates its revenue in the United States, with a growing presence in Europe.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.
Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.
Channel Medsystems is a medical device company offering cryotherapy devices for endometrial cryoablation. Its mission is to empower every woman to take control of her health journey and live their best life.
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Ceptaris Therapeutics, Inc. is a privately held specialty pharmaceutical company focused on developing a proprietary gel formulation of mechlorethamine hydrochloride for treating early-stage (stages I-IIA) mycosis fungoides, a form of Cutaneous T-Cell Lymphoma (CTCL). If approved, this investigational drug would be the first topical mechlorethamine product available for managing the signs and symptoms of this rare cancer. In addition to this primary focus, Ceptaris is also involved in developing other therapeutic products, including YT-1006, an NMDA antagonist aimed at treating neuropathic pain while minimizing side effects associated with NMDA. The company's innovative approaches enable healthcare professionals to address both dermatological and central nervous system disorders effectively.
Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.
Xlumena develops image-guided therapeutic endoscopy products. It develops Bile Duct Stenting, a self-expanding anchor stent and precision XL delivery system. The company also develops Pseudocyst Drainage, an integrated XF system designed to enable reliable pseudocyst drainage; and Hiatal Hernia Repair that enables the repair of a hiatal hernia from inside the GI lumen. Xlumena was founded in 2007 and is based in Mountain View, California.
CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.
CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.
Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.
TherOx operates as a private venture-financed medical device company based in Irvine, California. It is dedicated to elevating the standard of care for the treatment of heart attack patients. Its proprietary technology has been developed and iterated over a number of years and has been thoroughly studied in benchtop studies, animal studies, and clinical trials. Beyond the initial treatment of heart attack with SuperSaturated Oxygen Therapy (SSO2), TherOx has identified applications for SSO2 in stroke, oncology, and wound care. The Company currently holds 20 issued patents with additional applications pending.
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal. MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.
Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for unmet medical needs. Founded by experienced pharmaceutical executives, the company is engaged in creating new drugs and treatments for challenging illnesses. Its product portfolio includes Reslizumab, which is aimed at treating eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents that have the potential for oral administration. Additionally, Ception's offerings encompass treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. The company's research pipeline focuses on developing new compounds and expanding indications for existing therapies.
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.
MAKO Surgical is a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally. The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment. In 2011, The company was named the No.1 on the Technology Fast 500 as the fastest growing technology company by Deloitte and received the CSSEC Award for loyal, customer-focused staff members presented by the Technology Services Industry Association and ACE Award (Achievement in Customer Excellence) from MarketTools and Fast Tech Award as one of the 25 fastest growing technology companies in South Florida by South Florida Business Journal. MAKO Surgical was founded in 2004 and is headquartered in Florida, USA.
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.
TherOx operates as a private venture-financed medical device company based in Irvine, California. It is dedicated to elevating the standard of care for the treatment of heart attack patients. Its proprietary technology has been developed and iterated over a number of years and has been thoroughly studied in benchtop studies, animal studies, and clinical trials. Beyond the initial treatment of heart attack with SuperSaturated Oxygen Therapy (SSO2), TherOx has identified applications for SSO2 in stroke, oncology, and wound care. The Company currently holds 20 issued patents with additional applications pending.
Nina McLemore, LLC, founded in 2002 and based in New York, designs high-quality clothing for women, focusing on simple, elegant styles suitable for contemporary executives and community-active individuals. The collection includes jackets, skirts, pants, handmade jewelry, and accessories crafted from luxurious natural fibers sourced from top European mills. Nina McLemore emphasizes the versatility and timeless appeal of its designs, particularly jackets that can transform any outfit. The products are available through select specialty stores and exclusive sales consultants in various locations, including New York, San Francisco, and Aspen. Prices range from $65 to $900, offering a better value compared to more expensive designer collections while ensuring a great fit and vibrant colors for everyday office wear.
Redpoint Bio is following a strategy focused on preserving the value of the License and Commercialization Agreement it entered into with International Flavors and Fragrances, Inc. (IFF), a global leader in the food and beverage industry. As part of this strategy, the Company continues its efforts to reduce its liabilities and sell its remaining assets. Given its lack of resources, the Company is not currently performing any research and development activities.
Metra Biosystems specializes in the development and commercialization of diagnostic products aimed at detecting and managing metabolic bone and joint diseases. The company's focus is on creating innovative diagnostic devices that address disorders related to bone and cartilage. By providing accurate and reliable tools for healthcare professionals, Metra Biosystems contributes to improved patient care and outcomes in the field of metabolic bone health.